Skip to content

Zepbound

Also called tirzepatide weight loss, Zepbound pen.

By Dr Chad Okay3 min read

Zepbound is the US brand name Eli Lilly uses for tirzepatide when it is licensed for weight loss. It is the same drug as Mounjaro, just badged for a different licensed use. It activates both GLP-1 and GIP receptors and produces the largest average weight loss of any approved GLP-1 medication in trials.

Zepbound vs Mounjaro

Both are tirzepatide. Same molecule, same pen design, same dose ladder. The only differences are the brand name and the licensed indication. Mounjaro is licensed for type 2 diabetes (and, in the UK, for weight management as well). Zepbound is the US brand specifically for weight management and is not used outside the United States.

How it works

Tirzepatide activates GLP-1 and GIP receptors at the same time. Both are gut hormones released after meals. Activating both slows gastric emptying, raises insulin sensitivity, and signals fullness to the brain. The combined effect lowers appetite and total calorie intake without conscious effort.

What the trials showed

  • SURMOUNT-1: about 22.5% average weight loss at 72 weeks on the 15 mg dose, against 2.4% on placebo.
  • SURMOUNT-5 (head-to-head with semaglutide): 20.2% on tirzepatide vs 13.7% on semaglutide at 72 weeks.
  • Across SURMOUNT-1 doses, the share losing at least 5% of body weight was 85% on 5mg, 89% on 10mg, and 91% on 15mg (Jastreboff 2022). Around 36% on 15mg lost at least 25%.

Side effects

  • Nausea, especially after each dose increase. Usually settles within 1 to 2 weeks.
  • Constipation. SURMOUNT-1 reported around 12 to 17% across the dose range.
  • Diarrhoea, in a smaller number of users, often early in treatment.
  • Reflux, burping, fatigue.
  • Rare but serious: pancreatitis, gallstones, severe gastroparesis. Severe, persistent abdominal pain needs a doctor the same day, not a wait-and-see approach (see below).

If something feels wrong

This entry is reference information, not medical guidance. Your doctor and pharmacist know you and your medicine; if anything about how you feel worries you, speak to them promptly, and if you ever feel seriously unwell, treat it as an emergency. The medicine's own patient information leaflet carries the important safety information and is worth reading in full.

If you are in the UK

Zepbound is a US-only brand. The same drug is sold in the UK as Mounjaro for both diabetes and weight management. NICE TA1026 covers tirzepatide for adults with a body mass index (BMI) of 35 or over plus a weight-related condition. Per NICE: 'Tirzepatide can be used in primary care or specialist weight management services', NHS England is rolling it out in phases, starting in specialist services, but the NICE guidance does not restrict it to Tier 3.

Common questions

Yes, both are tirzepatide. Same molecule, same pen, same dose ladder. Different brand name and different licensed use. Zepbound is the US weight-loss brand. Mounjaro is the diabetes brand globally and the weight-management brand in the UK.

Built for this.

Suna is a wearable designed to help you see your own everyday patterns, without keeping a diary. Reservations open.

Sources

  1. 1Drugs@FDA: Zepbound (tirzepatide) NDA 217806, original approval for chronic weight management 8 November 2023US Food and Drug Administration
  2. 2Tirzepatide - StatPearls (dual GIP/GLP-1 receptor agonist mechanism; Mounjaro and Zepbound branding)StatPearls / NCBI Bookshelf
  3. 3SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff et al, 2022), >=5% responder rates, mechanism, AEsN Engl J Med (PMID 35658024)
  4. 4Zepbound (tirzepatide) prescribing information: oral hormonal contraceptives and delayed gastric emptying; adverse reactions by doseEli Lilly
  5. 5Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period (2024)Clinical Gastroenterology and Hepatology
  6. 6SURMOUNT-5: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (Aronne et al, 2025), 20.2% vs 13.7% at 72 weeksN Engl J Med (PMID 40353578)
  7. 7Tirzepatide mechanism of action: dual GIP/GLP-1 agonist, slows gastric emptying, induces satiety, improves insulin sensitivityInt J Mol Sci (PMC9741068)
  8. 8Khawaji 2025 meta-analysis: tirzepatide produces greater weight loss than GLP-1 receptor agonistsJournal of Obesity (PMC12313391)
  9. 9NICE TA1026: Tirzepatide for managing overweight and obesity, Recommendations (BMI >=35 + comorbidity; primary care or specialist services)NICE TA1026
Written by Dr Chad Okay. Contributor: Dr Parisah Hussain, MBChB, BSc (Hons), DRCOG, MRCGP. Last updated . From Digests.

Related reading

All Digests

About Digests

Digests explains how the body works in general, everyday terms. It is not medical advice. It is not a substitute for someone who can examine you and knows your history, and we do not tell you what dose of any medicine to take.

Where we describe how something is checked or looked after, we follow UK guidance from NICE and the NHS, so the tests and routes where you live may differ. The same concerns are worth taking to your own doctor.

Some articles explain approaches that researchers have studied, including gut-directed hypnotherapy. Explaining an approach is education, not an offer of it: Suna does not provide hypnotherapy or any medical or psychological treatment.

Suna Health is building a wearable wellness device for gut health and offers a gut-directed relaxation app, and you will see both advertised alongside these pages. That commercial interest does not decide what the content says.

If you think we have got something wrong, tell us at digests@suna.health. It goes to the editor. Full terms, including our liability position, are at suna.health/terms.

The wearable for gut health and nutrition. Built by a passionate team, grounded in peer-reviewed research.

Suna

Suna is a wellness device, not a medical or diagnostic device. It does not diagnose, treat, cure, or prevent any disease. The Suna app offers a five-week gut-directed relaxation program for general wellbeing. The program is a self-guided wellness practice: it is not medical care, not psychological treatment, and not hypnotherapy, and it is not a substitute for care from a qualified practitioner. Information provided is general wellness information, not medical advice. Always consult a qualified healthcare professional about any health concern.

Suna Health US, Inc., 2810 N Church St STE 90849, Wilmington, DE 19802

© 2026 Suna Health.